Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation
Authors' conclusion
In well-controlled T2D patients with ASCVD, the higher serum phospholipid LI is associated with worse glucometabolic control, enhanced vascular inflammation and higher platelet reactivity during aspirin treatment at cyclooxygenase-1-selective doses.
Study context
- Population
- T2D patients with angiographically documented atherosclerotic cardiovascular disease (ASCVD), aged 65.6 ± 6.8 years, median diabetes duration 10 years, median HbA1c 7.0%
- Participants
- 74 patients
- Exposure
- Serum phospholipid lipophilic index (LI) >16.9 °C vs ≤16.9 °C
- Outcome
- Glucometabolic control, vascular inflammation and platelet activation by LI
Main finding
As reported in the abstract
- Higher HbA1c with LI > 16.9 °C vs remaining subjects (p = 0.035)
- 5.9%
- Higher TCh with LI > 16.9 °C (p = 0.012)
- 17.1%
- Higher LDL-C with LI > 16.9 °C (p = 0.003)
- 29.4%
- Higher interleukin-6 with LI > 16.9 °C (p = 0.031)
- 22.2%
- Higher Lp-PLA2 with LI > 16.9 °C (p = 0.040)
- 32.4%
Observational data: associations, not effects.
Further findings
HbA1c ≥ 7.0%
P = 0.020
Correlations of serum phospholipid LI
- HbA1c (p = 0.037)
- r = 0.24
- TCh (p = 0.002)
- r = 0.36
- LDL-C (p < 0.001)
- r = 0.38
- Interleukin-6 (p = 0.020)
- r = 0.27
- Lp-PLA2 (p = 0.026)
- r = 0.26
Predictors of LI > 16.9 °C
- HbA1c ≥ 7.0% and serum LDL-C, interleukin-6 and Lp-PLA2 were predictors of LI > 16.9 °C
- Adjusted models
Original publication
Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation. Cardiovasc Diabetol. Published 15 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →